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1. Introduction 
Amyotrophic Lateral Sclerosis (ALS) is a devastating progressive neurodegenerative disease, 
due to the loss of motor neurons and denervation of muscle fibres, resulting in increasing 
muscle weakness and paralysis. The disease has an incidence of 2.7 cases per 100,000 people in 
Europe (Longroscino et al., 2010). It is diagnosed from teen years onward, but is more 
prevalent in the later years of life. In lack of a medical cure, average life expectancy post 
diagnosis is between 2 and 5 years, though 10% of all patients live longer than 10 years. 
Patients mainly succumb to the disease by respiratory insufficiency or may opt for euthanasia 
where legislature permits (Maessen et al., 2010). Although ALS is characterised by 
degeneration of central nervous system tissue, mental functions remain largely unaffected 
resulting in a locked-in state (Kotchoubey et al., 2003). At current, there is but one medicine to 
treat the disease, riluzole, slowing disease progression moderately (Miller et al., 2007). 
1.1 Basic genetics of ALS 
Mutations in the ubiquitously expressed Cu/Zn superoxide dismutase 1 (SOD1) gene 
can cause ALS. SOD1 detoxifies cell damaging free radicals and its mutations account for 
20% of the ALS patients suffering from the disease by familial origin (fALS) worldwide. 
The remaining 90% of ALS patients suffer from the disease by unknown sporadic causes 
(sALS), though a common mechanism is predicted as fALS and sALS patients display  
indistinguishable clinical phenotypes. Overexpression of mutant forms of human SOD1 
causes the ALS phenotype of transgenic SOD1 mice, accounting for an invaluable 
contribution to ALS research (Gurney et al., 1994). Many hallmarks of the disease are 
shared between patients and this rodent model, including specific motor neuron loss, 
aggregate formation, astrogliosis, microgliosis and progressive paralysis. As the genetic 
ablation of SOD1 does not produce an ALS-like phenotype in mice (Reaume et al., 1996; 
Shefner et al., 1999) the pathogenic mechanism of mutant SOD1 is a toxic gain of 
function. This gain of function may be exerted by protein misfolding, aggregation, 
impaired proteasome functioning, impaired retrograde transport, excitotoxic cell death 
or other mechanisms (reviewed in Bruijn et al., 2004). Mutations in other genes also 
cause familial ALS, including mutations in vesicle-associated membrane protein-
associated protein B (VAPB), TAR DNA binding protein (TDP-43), fused in 
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sarcoma/translocated in liposarcoma (FUS/TLS), optineurin and valsolin containing 
protein (VCP) (Johnson et al.; Maruyama et al.; Rutherford et al., 2008; Van Deerlin et al., 
2008; Del Bo et al., 2009; Kwiatkowski et al., 2009; Vance et al., 2009). Unfortunately, the 
discovery of these mutant genes has not yet progressed into useful ALS model 
organisms, so most of the work described below was conducted with mutant SOD1-
based ALS models.  
1.2 Non-cell autonomous ALS 
Multiple cell types contribute to the pathology making ALS a non-cell autonomous disease 
(Boillee et al., 2006a). By addition or deletion of mutant SOD1 in specific cell types, it is 
known that mutant SOD1 influences the disease depending on the cell type, including 
astrocytes (Yamanaka et al., 2008; Wang et al., 2011a), microglia (Boillee et al., 2006b), 
Schwann cells (Lobsiger et al., 2009) and motor neurons (Jaarsma et al., 2008). Additionally, 
ablation of T-cells (Beers et al., 2008; Chiu et al., 2008), B-cells (Naor et al., 2009), CD4+ and 
CD8+ cells (Beers et al., 2008) decrease survival of ALS mice, demonstrating the role of 
immune cells in disease progression. Although ALS is a non-cell autonomous disease, 
mutant SOD1 expressed solely in motor neurons is sufficient to initiate the disease, albeit 
with a slower disease progression (Jaarsma et al., 2008). Motor neurons in the motor cortex, 
brainstem and spinal cord undergo cell death selectively in patients. A number of 
hypotheses attempt to explain this cell type selectivity, including the long axons of the 
motor neurons (Fischer and Glass, 2007), their poor intracellular calcium buffering capacity 
(Grosskreutz et al., 2010) and motor neuron specific cell death pathways (Raoul et al., 2002; 
Raoul et al., 2006; Genestine et al., 2011).  
The contribution of mutant SOD1 expressing astrocytes in the non-cell autonomous character of 
ALS has been studied by excising mutant SOD1 from astrocytes which increases survival in two 
different mutant SOD1 mouse models (Yamanaka et al., 2008; Wang et al., 2011a). These results 
denote the toxic character of mutant SOD1 in astrocytes that accelerate disease progression 
significantly by mechanisms such as, but not exclusively, the below described mechanisms of 
neuroinflammation and excitotoxicity. This is schematically presented in figure 1. 
1.3 Neuroinflammation observed in ALS 
Neuroinflammation occurs in a number of neurodegenative diseases, including ALS 
(reviewed in Papadimitriou et al., 2010 and Philips and Robberecht, 2011), and entails the 
reactive state of astrocytes (astrogliosis) and microglia (microgliosis) and the infiltration of 
lymphocytes. Initially perceived as a bystander effect, neuroinflammation is currently seen 
as beneficial at first, removing damaged cells and secreting supportive factors, and 
potentially detrimental thereafter by excessive release of cytokines (Beers et al., 2011a). 
Evidence of inflammation is detected in post mortem tissue (Schiffer et al., 1996; Anneser et 
al., 2004; Casula et al., 2011; Sta et al., 2011; Wang et al., 2011b), in cerebrospinal fluid (CSF) 
(Baron et al., 2005; Tateishi et al., 2010) and in blood samples of ALS patients (Poloni et al., 
2000). In accordance, similar parameters of neuroinflammation are detected in ALS rodent 
models (among many others in Kiaei et al., 2006; Keller et al., 2009; Beers et al., 2011b). 
Inflammation is generally perceived as hazardous in ALS, as increasing inflammation in 
ALS models exacerbates disease progression and diminishes survival (Nguyen et al., 2004; 
Gowing et al., 2009). Fittingly, therapeutic strategies targeting inflammation are often 
advantageous in ALS rodent models (see below). 
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1.4 Excitotoxicity in ALS 
An additional detrimental mechanism in ALS is excitotoxicity; an overstimulation of 
neurons causing neurodegeneration. Glutamate binds to the N-methyl D-aspartate (NMDA) 
or ǂ-amino-3-hydroxy-5-methyl-4-isoxazole proprionic acid (AMPA) receptors, allowing 
extracellular sodium and calcium to enter motor neurons. Increased levels of intracellular 
calcium consequently cause neuronal cell death. The importance of excitotoxicity in ALS is 
demonstrated by the beneficial effects obtained by treating patients with riluzole. Although 
the precise mechanism of this drug is not yet known, it blocks NMDA receptors, enhances 
re-uptake of glutamate from the synaptic cleft and inhibits glutamate release by blocking 
voltage-gated sodium channels (Siniscalhi et al., 1999), thus preventing motor neuron cell 
death. Riluzole treatment increases predicted lifespan with a significant 12% in ALS mice 
(Bensimon et al., 1994; Lacomblez et al., 1996) and increases the probability of one year 
survival in patients by 9% (Miller et al., 2007). Unfortunately, it does not halt disease 
progression.  
An overview of the current knowledge of the astrocytic contribution in ALS will be 
addressed in this chapter separately for the mechanisms inflammation and excitotoxicity. 
2. Astrocytes in inflammation 
Despite that microglia are the main immune cells of the central nervous system (reviewed in 
Ransohoff, 2010), astrocytes can also become reactive and contribute to neuroinflammation 
and are the focus of this chapter, with microglial inflammatory effects residing beyond the 
scope of this chapter. During neuroinjury or neurodegeneration the production of cytokines 
induce astrogliosis in which astrocytes increase glial fibrillary acidic protein (GFAP) and 
vimentin expression as well as an array of other genes. This response increases neuronal 
survival and includes both supportive factors (e.g. growth factors and glutamate 
transporters) and cytokines to sustain/promote neuroinflammation. Interestingly, during 
neuroinflammation the number of astrocytes increases by the differentiation of chondroitin 
sulfate proteoglycan, NG2, positive cells to astrocytes and not by astrocytic proliferation 
(Gowing et al., 2008).  
2.1 Increasing inflammation in ALS 
To assess the effect of inflammation in ALS and thus to discover whether boosting the 
inherent inflammation would be beneficial, lipopolysaccharide (LPS) was daily 
administered to ALS mice (Nguyen et al., 2004). The effect of this treatment was a clear 
decrease in lifespan, implying that an increase of inflammation is detrimental in ALS 
(Nguyen et al., 2004). Another study, initially intended to decrease inflammation, 
administered macrophage colony stimulating factor (M-CSF) to ALS mice and observed an 
unexpected increase of microgliosis also leading to a decreased survival (Gowing et al., 
2009). Although not directed specifically at astrocytes, this work has led to the 
understanding of the hazardous character of neuroinflammation in ALS. 
2.2 Astrogliosis in ALS 
Reactive astrocytes alter gene expression including an upregulation of the intermediate 
filaments GFAP and vimentin that allow for visualisation of astrogliosis by increased 
immunoreactivity of these filaments in patient and ALS model tissue. Post mortem spinal 
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cord tissue from fALS and sALS patients display astrogliosis (Schiffer et al., 1996), implying 
that reactivity of astrocytes is not limited to the familial form of ALS. Interestingly, 
astrogliosis levels are similar between long surviving and short surviving ALS patients, 
although this is not the case for microglial activation and the amount of dendritic cells (Sta 
et al., 2011). An extra facet of astrogliosis in ALS is an increased immunoreactivity of toll-
like receptor 4 in astrocytes of sALS patients (Casula et al., 2011). Astrogliosis in ALS mice is 
present at symptomatic stages preceeding microgliosis (Kiaei et al., 2006; Keller et al., 2009; 
Yang et al., 2011). Interestingly, GFAP is not necessary for astrogliosis as GFAP deficient 
astrocytes can still become reactive and do not affect survival of ALS mice (Yoshii et al., 
2011).  
2.3 Mutant SOD1 affects astrocytic inflammatory behaviour 
The expression of mutant SOD1 in astrocytes alters their function in vivo and in vitro. To 
begin, deletion of mutant SOD1 in astrocytes in two distinct ALS models demonstrates the 
detrimental effect of mutant SOD1 in astrocytes mainly post onset, as deletion increased 
lifespan of ALS mice (Yamanaka et al., 2008; Wang et al., 2011a). Intriguingly, astrogliosis 
was unaltered, implying that the negative effect of mutant SOD1 in astrocytes is not due to 
altered levels of astrogliosis (Yamanaka et al., 2008), but potentially by astrocytes inducing 
microgliosis (Yamanaka et al., 2008; Wang et al., 2011a). An alternative approach arrives 
from the field of transplantation in which non-transgenic mesenchymal stem cells are 
transplanted into the spinal cord of ALS rats and differentiate into astrocytes, thus diluting 
the mutant SOD1 positive astrocytes in the spinal cord (Boucherie et al., 2009). This 
approach also shows unaltered astrogliosis, but also decreased microgliosis and 
cyclooxygenase 2 (COX2) expression, and extends murine ALS life span (Boucherie et al., 
2009). The processes explaining this hazardous effect of mutant SOD1 in astrocytes has been 
investigated in vitro. To begin, an interesting approach of transducing human astrocytes 
with wild-type SOD1 or mutant SOD1 increases inflammation in mutant SOD1 cultures 
(Marchetto et al., 2008). In addition, the mutant SOD1 transduced astrocytes provide a less 
viable environment for human embryonic stem cell derived motor neurons (Marchetto et al., 
2008). The latter was rescued by using a NADPH oxidase 2 (NOX2) inhibitor, apocynin 
(Marchetto et al., 2008). Other studies concur that mutant SOD1 primary astrocytes exhibit a 
higher gene expression of cytokines on baseline and when stimulated by interferon Ǆ (IFNǄ) 
or tumor necrosis factor ǂ (TNFǂ) (Hensley et al., 2006), implying once again that mutant 
SOD1 expression may affect the threshold of astrocytes to produce proinflammatory 
cytokines. Accordingly, the expression of interferon simulated genes is detected in 
astrocytes of presymptomatic ALS mice (Wang et al., 2011b) and genetic ablation and 
knockdown of the interferon alpha receptor type 1 (IFNAR1) increase ALS mouse survival 
by 5% and 10%, respectively (Wang et al., 2011b). Intriguingly, Aebischer et al. stress the 
importance of interferon signalling in mutant SOD1 astrocytes by demonstrating that 
mutant SOD1 astrocytes trigger the selective death of motor neurons mediated by IFNǄ 
(Aebischer et al., 2011). This mechanism is dependent on the activation of the lymphotoxin-ǃ 
receptor by LIGHT (TNFSF14) and genetic ablation of LIGHT extends survival of ALS mice 
by 13%, but does not postpone disease onset (Aebischer et al., 2011). Although this is a large 
increase in disease survival, clearly other mechanisms remain to play a role.  
The above described altered functioning of mutant SOD1 expressing astrocytes is induced 
by an overexpression of multiple copies of mutant SOD1. It is unclear whether these effects 
www.intechopen.com
 The Astrocytic Contribution in ALS: Inflammation and Excitotoxicity 
 
381 
also play a role in fALS patients with only 1 allele of mutant SOD1 or in fALS/sALS patients 
without disease causing SOD1 mutations. Remarkable work by Haidet-Phillips et al., (2011) 
shows that astrocytes collected post mortem from fALS and sALS are both able to induced 
motor neuron selective death which is not observed with astrocytes obtained from controls 
(Haidet-Phillips et al., 2011). Gene expression analysis of the the fALS and sALS astrocytes 
demonstrated increased expression chemokines, proinflammatory cytokines and 
components of the complement pathway (Haidet-Phillips et al., 2011). This study confirms 
that the astrocytic inflammatory effects found in vitro and in vivo in ALS mice may also 
contribute to disease pathology in humans. 
2.4 Genetic tools to minimise astrogliosis 
Attempts to minimise the inflammatory effect of astrocytes in ALS include genetic 
strategies targeting astrocytic knockdown of certain cytokines. Targeting of nuclear factor 
κB (NF-κB) activation specifically in astrocytes does not alter disease onset nor life span in 
ALS mice (Crosio et al., 2011). Which may be in part due to the mere decreased 
astrogliosis at presymtomatic stage (Crosio et al., 2011). Additionally, complete ablation of 
TNFǂ does not affect disease parameters (Gowing et al., 2006), also  implying deletion of a 
single cytokine may not be sufficient to affect disease progression, as a general decrease in 
inflammation can be beneficial (see below). Instead of targeting cytokine production, 
ablating proliferating astrocytes was attempted in ALS, showing no effect on survival 
(Lepore et al., 2008a). This may be explained by the inability of astrocytes to proliferate in 
ALS (Gowing et al., 2008). 
2.5 Therapeutic strategies targeting inflammation in ALS  
A number of strategies have been utilized to diminish inflammation in ALS mice, though 
often not specifically targeting astrocytes. It is worthwhile to note that it is commonly 
unclear whether anti-inflammatory strategies truly exert an anti-inflammatory function 
due to the age-matched analysis of astrogliosis instead of disease stage-matched analysis 
with drugs that successfully extend lifespan. Among these therapeutic strategies are those 
intended to pharmacologically block the cyclooxygenase (COX) pathway by 
administration of celecoxib, a selective COX-2 inhibitor, and deletion of the prostaglandin 
E2 receptor. Both strategies diminish inflammation, postpone disease onset and prolong 
survival in ALS mice (Drachman et al., 2002; Liang et al., 2008). Similarly, celastrol 
administration also postponed disease onset extended lifespan, while decreasing TNFǂ, 
nitric oxide synthases (iNOS), cluster of differentiation 40 (CD40) immunoreactivity and 
astrogliosis when assessing age-matched spinal cord tissue (Kiaei et al., 2005). Similar 
effects are obtained when providing ALS mice with folic acid (Zhang et al., 2008) or bee 
venom (Yang et al., 2010). Thalidomide extends survival in ALS mice by destabilising 
cytokine mRNA including TNFǂ (Kiaei et al., 2006). Additionally, its analog lenalidomide 
also prolongs survival (Kiaei et al., 2006), even when administered after symptom onset 
(Neymotin et al., 2009). To conclude, minocycline has shown a dramatic increase in 
survival of ALS mice and postpones symptom onset (Kriz et al., 2002; Van Den Bosch et 
al., 2002; Zhu et al., 2002). Interestingly, this effect is moment of administration 
dependent, as administration of minocycline post disease onset increases the astrocytic 
and microglial response in ALS mice, decreasing survival (Keller et al., 2011). 
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Fig. 1. Mutant SOD1 in astrocytes affecting (motor) neuron survival. 
3. Astrocytes in excitotoxicity 
In addition to the clear inflammatory role that astrocytes play in ALS, they also contribute to 
the mechanism of excitotoxicity. Their effect in the latter mechanism is two-fold: firstly, 
astrocytes facilitate the removal of excessive glutamate at the synaptic cleft and secondly, 
they affect the calcium permeability of AMPA receptors of motor neurons. 
3.1 Excitotoxicity in ALS explained 
Glutamate is the initiator of excitotoxicity in ALS. This neurotransmitter is the most 
abundant excitatory neurotransmitter in the brain and binds to NMDA, AMPA, and kainate 
(ionotropic) and metabotropic glutamate receptors (mGluR). Packaged into vesicles by the 
pre-synaptic neuron, glutamate is released into the synaptic cleft by the fusion of vesicles to 
the membrane of the neuron to excite the post synaptic neuron. This process is inhibited by 
riluzole (Siniscalhi et al., 1999). Increased levels of glutamate are detected in fALS, sALS 
(Fiszman et al., 2010; Spreux-Varoquaux et al., 2002) and is confirmed in spinal cords of ALS 
mice and rats. The detrimental role of glumate in the disease is demonstrated by the 
pronounced cell death that occurs to neurons in vitro when exposed to low levels of 
glutamate, even as low as physiologically detected in CSF (Cid et al., 2003). To further 
illustrate the detrimental role of glutamate in ALS, administration of compounds that block 
the formation of glutamate increase cell survival, both in vivo and in vitro (Cid et al., 2003).  
3.2 Astrocytes in excitotoxicity in ALS: EAAT2/GLT-1 
After glutamate release from the pre-synaptic neuron and binding of glutamate to 
ionotropic or metabotropic receptors on the post-synapse (increasing the concentration of 
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intracellular calcium), glutamate is recycled for further use by the glial and endothelial cells, 
including astrocytes. Astrocytic glutamate re-uptake occurs by the glutamate transporters 
excitatory amino acid transporter 1 (EAAT1) and excitatory amino acid transporter 2 
(EAAT2; also known as glutamate aspartate transporter (GLAST1) and glutamate 
transporter 1 (GLT-1), respectively). These transporters internalise glutamate, eg. into the 
astrocyte, for conversion to glutamine that is returned to the pre-synaptic neuron to be 
release again as glutamate (Laake et al., 1995).   
Decreased glutamate uptake and EAAT2 protein levels are a common feature in both fALS 
and sALS and both in vitro and in vivo model systems (Staats and Van Den Bosch, 2009). In 
vitro transfection of primary cultured astrocytes with either mutant SOD1 or wild type 
human SOD1 down-regulates EAAT2 post transcriptionally (Tortarolo et al., 2004) and 
decreases EAAT2 transcription (Yang et al., 2009). Accordingly, glutamate transport is 
decreased in a neuronal cell line by mutant SOD1 transfection (Sala et al., 2005). 
Interestingly, this down-regulation also occurs in ALS model rats at pre-symptomatic stages 
through to end stage (Howland et al., 2002), at end stage only (Warita et al., 2002), in ALS 
model mice at end stage (Bendotti et al., 2001; Guo et al., 2010) and in post mortem patient 
spinal cords (Sasaki et al., 2001). In addition, in patient material the loss of EAAT2 and 
decreased tissue glutamate transport does not coincide with decreased levels of gene 
expression (Bristol and Rothstein, 1996), indicating that the loss is induced post 
transcriptionally, also in humans. Interestingly, a decrease of EAAT2 protein levels is not 
only in mutant SOD1 ALS models, but also a model of ALS/PDC (Wilson et al., 2003). In 
this model wild-type mice are fed with washed cycad flour containing ǃ-methylamino-
alanine (BMAA), which causes an ALS-like phenotype (Wilson et al., 2002). Although the 
loss of EAAT2 in ALS is apparent, it remains unclear whether this post transcriptional loss 
of EAAT2 proceeds or follows the loss of motor neurons.  
3.3 Targeting (astrocytic) EAAT2 
To assess whether the loss of glutamate transport or the loss of EAAT2 specifically results in 
motor neuron loss, pharmacological and genetic tools have been used. To begin, research 
conducted by pharmacologically inhibiting glutamate transport in the rat spinal cord, failed 
to show any motor neuron loss despite the increased levels of glutamate (Tovar et al., 2009). 
In contrast, a similar experiment has been performed to address whether EAAT2 loss 
specifically induces motor neuron loss. EAAT2 null mice live for approximately 6 weeks 
before they succumb to epileptic seizures and are vulnerability to acute brain injury (Tanaka 
et al., 1997). To this end, heterozygous mice demonstrated the effect of approximately 40% 
knockdown of EAAT2 in the spinal cord in ALS mice (Pardo et al., 2006). This knockdown 
resulted in a non-significant decrease of symptom onset and significant, but moderate, 
decrease of lifespan in ALS mice (Pardo et al., 2006). 
To assess the expected beneficial role of EAAT2 in ALS, transgenic mice overexpressing 
human EAAT2 in specifically astrocytes were crossbred with mutant SOD1 mice. Although 
glutamate uptake is increased in vivo and an overexpression of human EAAT2 is protective 
on cortical neurons in vitro, an effect on symptom onset or lifespan was absent (Guo et al., 
2003). Possibly, the expression levels were insufficient to induce an effect or human EAAT2 
is not as efficient as murine EAAT2 in mouse, as administration of ceftriaxone (a ǃ-lactam 
antibiotic) and GPI-1046 (a synthetic, non-immunosuppressive derivative of FK506) increase 
EAAT2 protein levels and extend lifespan of ALS mice (Rothstein et al., 2005; Ganel et al., 
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2006) by enhancing EAAT2 transcription (Lee et al., 2008). In addition, EAAT2 is also 
expressed by other cells types than astrocytes alone (Anderson and Swanson, 2000), which 
are not targeted in this genetic experimental design. Interestingly, removal of mutant SOD1 
from astrocytes leads to prolonged survival without affecting astrogliosis, but does preserve 
EAAT2 levels potentially explaining the extended lifespan (Wang et al., 2011a). 
3.4 Astrocytic replacement therapy in ALS mice 
The beneficial effect of EAAT2 is often used as an explanation of positive effects found by 
cell transfers in ALS model rodents. For instance, the systemic transplantation of c-kit 
positive cell from bone marrow in mutant SOD1 mice significantly increased the lifespan, 
which is, at least in part, attributed to increased EAAT2 expression induced by the 
transferred cells (Corti et al., 2010). The same holds true for the prolonged survival of ALS 
rats when treated with focal transplantation-based astrocyte replacement with wild type 
glial-restricted precursors (GRPs) (Lepore et al., 2008b). This study also focussed on EAAT2 
by also transplanting EAAT2 overexpressing GRPs and EAAT2 null GRPs. The ALS mice 
treated with the EAAT2 overexpressing GRPs showed no additional increase of lifespan 
compared to wild type GRP treated ALS mice (already increased compared to controls). 
Intriguingly, this positive effect of transplantation of the wild type GRPs is diminished in 
mice transplanted with EAAT2 null GRPs (Lepore et al., 2008b). In addition, co-cultures of 
human adipose-derived stem cells with astrocytes induce higher levels of EAAT2 in 
astrocytes (Gu et al., 2010), though this treatment has not (yet) been shown to affect motor 
neuron survival in vitro or in vivo. 
3.5 Astrocytes in excitotoxicity in ALS: AMPA receptor permeability 
After the release of glutamate from the pre-synaptic neuron into the synaptic cleft, glutamate 
binds to NMDA, AMPA receptors or the metabotropic receptors. High levels of calcium 
entering through AMPA receptors into the post-synaptic neuron can cause neuronal death. 
The AMPA receptor is formed as a tetramer combining, usually pairwise, a combination of its 
four different subunits (glutamate receptor unit 1-4 (GluR1-4)) (Shi et al., 1999). Each subunit 
can bind glutamate and the channel opens after occupation of at least 2 binding locations 
(Mayer, 2005). The importance of this receptor in ALS is demonstrated by the ablation of 
glutamate induced apoptosis in cortical neurons in vitro (Cid et al., 2003) and in vivo when 
administering an AMPA receptor antagonist (Van Damme et al., 2003; Tortarolo et al., 2006).  
The AMPA receptor plays an imperative role in excitotoxicity by its calcium permeability 
that is determined by the incorporation of the GluR2 subunit in the receptor complex. In 
most conditions, the AMPA receptor complex contains at least one GluR2 subunit and it 
prevents the influx of extracellular calcium into the neuron (Seeburg et al., 2001). In contrast, 
receptors lacking the GluR2 subunit are highly calcium permeable (Seeburg et al., 2001). A 
general decrease of GluR2 is found in ALS model mice, portraying an increased 
vulnerability of these mice to excitotoxic insults (Tortarolo et al., 2006; Zhao et al., 2008). The 
role of GluR2 in ALS is investigated by genetically ablating GluR2 in ALS mice, which 
decreases survival in vivo and decreases cell survival in vitro (Van Damme et al., 2005). The 
opposite has been shown by up-regulating GluR2 expression in motor neurons of ALS mice, 
as hereby survival is increased (Tateno et al., 2002). In addition, pharmacological inhibition 
of the AMPA receptor prolonged survival in ALS model mice (Van Damme et al., 2003; 
Tortarolo et al., 2006).  
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Interestingly, the surrounding astrocytes influence the expression level of the GluR2 subunit 
in motor neurons, as soluble factor(s) released from astrocytes effect GluR2 gene expression 
and neuronal vulnerability to excitotoxic insults, both in vitro and in vivo (Van Damme et 
al., 2007). Moreover, the presence of mutant SOD1 interferes with the production and/or 
secretion of this factor(s) to increase GluR2 expression and thus decreases motor neuronal 
resistance to excitotoxicity (Van Damme et al., 2007).  
4. Conclusions and future directions 
Astrocytes clearly contribute to ALS decrease progression in both neuroinflammation 
and excitotoxicity. An intriguing aspect of astrocytes in ALS disease pathology is 
whether the mutant SOD1 astrocytic properties, of LIGHT dependent cell death and 
diminished GluR2 editing for example, are also important in other ALS causing 
mutations and in sporadic cases of ALS. Initial work performed implies that these 
characteristics are not solely dependent on mutant SOD1 in patients. In addition, both 
mechanisms in which astrocytes function seem successfully targetable in mice. Future 
research may benefit from further assessing the role of also non-SOD1 ALS causing 
mutations in astrocytes on ALS and optimizing therapeutic strategies against 
neuroinflammation and excitotoxicity. 
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